Phase IIRecruiting

CAR-T Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kite Pharma (Gilead)·NCT05834512·Lymphoma

Duration

24 months

Cost

Free to Patients

Phase

Phase II

Closes

Sep 2026

About This Trial

Evaluating axicabtagene ciloleucel (Yescarta) in relapsed or refractory DLBCL patients after 2+ prior therapies.

Houston, TX

New York, NY

Los Angeles, CA

Condition focus: Lymphoma

Available in: US

All study medications and visits are provided at no cost to participants

Your health data is protected under HIPAA / GDPR / UAE PDPL regulations

You may withdraw from the trial at any time without penalty

Specific eligibility criteria (age ranges, lab values, prior medications) will be confirmed by the study coordinator after you express interest.

Only 8 spots remaining

Apply soon to secure your place.

Trial Summary

NCT NumberNCT05834512

SponsorKite Pharma (Gilead)

PhasePhase II

Duration24 months

ClosesSep 2026

ConditionLymphoma